Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important kidney and cardiovascular benefits in adults with chronic kidney disease. Among adults with diabetes, we characterized the prevalence of chronic kidney disease eligible for SGLT2 inhibitor treatment, based on definitions of eligibility from trials and diabetes guidelines, and assessed the predictors of SGLT2 inhibitor use.

Methods

We conducted a cross-sectional study using linked administrative data from Alberta Health in adults with diabetes (2002-2019). Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) less than 90 mL/min/1.73 m² with severe or greater proteinuria (trial-based definition); or eGFR less than 60 mL/min/1.73 m² or moderate or gr

SUBMITTER: Lau D 

PROVIDER: S-EPMC9894653 | biostudies-literature | 2023 Jan-Feb

REPOSITORIES: biostudies-literature